1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

Generic Combination Products May Be Permitted Delivery Device Variations

 
• By Derrick Gingery

But US FDA officials say brand vs. generic product differences won't be appropriate in all cases and patient misuse remains a concern.

Machinery cogwheels, industry concept

US FDA officials seem open to some delivery device differences to make it easier for generic combination products to reach the market, but acknowledged the difficulties of balancing product variations with safety concerns.

For example, variation in the sets of instructions for uses of products dispensed through a pharmacy is potentially problematic, Badrul...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

US FDA’s ANDA Prioritization Pilot Encouraging Production Onshoring

 
• By Dave Wallace

The latest incentive for firms to move manufacturing to the US is an FDA pilot program that will prioritize the review of US-manufactured and tested ANDA products.

Evita’s Mifepristone Approval Reignites Abortion Pill Controversy

 
• By Dave Wallace

An FDA approval of Evita Solutions' generic mifepristone 200mg tablets has reignited debate about the abortion pill, which Health and Human Services Secretary Robert F. Kennedy Jr. has indicated will be subject to a safety review.

US FDA Gives Leucovorin Unprecedented Path To New Claim Amid ‘Autism Crisis’

 
• By Bridget Silverman

The Trump Administration's autism campaign convinced GSK to submit an sNDA for its no-longer-marketed leucovorin as a treatment for a rare folate deficiency condition with promises to ensure insurance coverage for autism.

Swissmedic Slashes Months Off Review Time For Certain Drug Filings

 
• By Anabel Costa-Ferreira

Switzerland’s health care products agency said it had cut the time it takes to review marketing applications for certain drugs submitted via its regulatory reliance procedure because it wants to further enhance the appeal of the pathway.

More from Biosimilars & Generics

How Will Trump’s Visa Brick, Rubio’s Tariff Fix, Lower Domestic Tax Impact Indian Pharma?

 
• By Vibha Ravi

As US Secretary of State Marco Rubio hints at reconsideration of a punitive Russian oil tariff, Trump adds an H-1B visa brick to his trade wall and India lowers GST on cancer and rare disease drugs, the Pink Sheet considers the impact.

US FDA Gives Leucovorin Unprecedented Path To New Claim Amid ‘Autism Crisis’

 
• By Bridget Silverman

The Trump Administration's autism campaign convinced GSK to submit an sNDA for its no-longer-marketed leucovorin as a treatment for a rare folate deficiency condition with promises to ensure insurance coverage for autism.

Korea’s New Health Minister: ‘Golden Time For The Country To Become A Biopharma Leader’

 
• By Jung Won Shin

Multiple Korean ministries, biopharma companies, and other officials convened at a bio innovation roundtable to discuss strategies to emerge as a global biopharma powerhouse.